Search

Displaying results 2921 - 2930 of 8575 in total
  1. Drug

    Prazosin

    go.drugbank.com/drugs/DB00457
    ApprovedInvestigational

    Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists.

  2. Drug

    Amfecloral

    go.drugbank.com/drugs/DB08924
    Experimental

    For a short period of time, it was available under the brand Acutran and indicated as an appetite suppressant, but this product no longer exists. … It acts as a prodrug which splits to form amphetamine and chloral hydrate, similarly to clobenzorex and related compounds, except that the N-substituent, in this case, yields a compound that is active

  3. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    [A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific

  4. Drug

    Etynodiol

    go.drugbank.com/drugs/DB13866
    Experimental

    Etynodiol (INN), or ethynodiol (BAN) is a steroidal progestin related to norethisterone which was never marketed. … While etynodiol is sometimes used as a synonym for etynodiol diacetate, it usually refers to etynodiol diacetate (see [DB00823]), not etynodiol.

  5. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [L10169] It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. … [A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017.

  6. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … In May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL.

  7. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.

  8. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    [A182039,A182045] Newer generations of DNA minor groove binding agents can more specifically recognize base pair sequences.[A182051] … [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity

  9. Drug

    Metandienone

    go.drugbank.com/drugs/DB13586
    ApprovedWithdrawn

    It was introduced to the market in the 1960s but later discontinued and withdrawn from the market. … Although it is prohibited in and outside competition by the World Anti-Doping Agency, metandienone continues to be marketed and misused as a performance-enhancing drug in sports.

  10. Drug

    Polycarbophil

    go.drugbank.com/drugs/DB09311
    ApprovedWithdrawn

    Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali.